Summer 2022

SNIP

A newsletter of the Society on NeuroImmune Pharmacology

Introduction

by Ilker K. Sariyer, D.V.M., Ph.D.

In this issue:

Hello to SNIP family from the new Society's newsletter edited by Communication Committee. Society's newsletter is the official publication of SNIP which reports the activities of the Society, including recent and upcoming meetings and news and announcements of interest to the majority of the SNIP members. In this issue, we report the 2022 Memphis meeting summary, ECI and DISC travel awardees, an article on pluripotent stem cell models of neuroHIV research, our official SNIP journal NIPT, and announcement of 2023 SNIP meeting. I want to express my special thanks to the members of the Communication Committee for their contributions in the preparation of the newsletter. We would like to also express our special thanks to everyone who attended and were involved in organization of the 26th SNIP conference in Memphis.

President's Message

Santosh Kumar, Ph.D., SNIP President

Dear SNIP members,

I hope that you and your family and friends are well and staying safe during the post-COVID era. I understand that the persistence of the pandemic has made our life and job relatively difficult. However, we have learned to live with it safely and productively. Especially, I admire all the early career investigators and their mentors to stay course despite the pandemic. As you know under the leadership of President Sulie Chang, despite the pandemic, we organized a virtual SNIP workshop in 2020 on SARS-CoV-2, and it was a grand success. Furthermore, since we could not do our planned 26th SNIP annual conference in New Delhi, India, the SNIP councils decided to do the 26th annual conference in USA. Thanks to the leadership team at the University of Tennessee Health Science Center (UTHSC) and College of Pharmacy (COP), the SNIP was able to organize the conference at the UTHSC-COP, Memphis on June 1-3, 2022. The brief report of the conference is published in the society new journal, "NeuroImmune Pharmacology and Therapeutics (NIPT)". I thank Dr. Howard Gendelman, the Editor-in-Chief, managing editor, Mr. Doug Meigs, and NIPT editorial members for publishing the conference report in very short time. The SNIP councils and SNIP meeting and local organizing committees led by Dr. Chandravanu Dash and myself put together an exciting event at the conference. As most of you have seen first-hand, we organized nine symposia including president, ECI, DISC-ECI, local, and general (selected from general abstracts) symposia along with several plenary and special lectures as well poster and speed-mentoring sessions. Overall, we had ~60 oral talks and as many posters. We had 165 registrations and 160 attendance in-persons. These numbers are similar to the numbers we usually have at our annul conference at a hotel in an exotic city. This clearly suggests the enthusiasm and cooperation for in-person conference among our SNIP members. Thank you, SNIPers! We concluded the conference with Thanking notes to UTHSC leadership and local organizing committee and their volunteers, award ceremony, and announcement of the 27th SNIP annual conference at the LaLiT Hotel (https://s-nip.org/conferences) in New Delhi, India from March 15-18, 2023. On behalf of the current SNIP EC members and councils, I sincerely thank you for a successful conference at UTHSC-COP, Memphis. I also take this opportunity to invite you to the 27th SNIP annual conference in New Delhi. Please feel free to contact me 24/7 using my email ksantosh@uthsc.edu or cell phone 409-370-1664 if you may need any additional information.

2022 SNIP Meeting Summary

By Santhi Gorantla, Ph.D.

The 26th Scientific Conference of the Society on NeuroImmune Pharmacology (SNIP) was held during June 1-3, 2022, at the University of Tennessee Health Science Center in Memphis, Tennessee. For many it is the first in-person meeting since the start of SARS-CoV-2 pandemic. SNIP conducted a one-day virtual workshop in 2021 on COVID-19 and this year it is the first full-sized three-day in person meeting.

The meeting included pre-conference workshop, a diversity and inclusion SNIP committee (DISC) session, scientific sessions, poster session, early carrier investigator (ECI) mentoring session.

Poster session

On June 1st, the pre-conference workshop was organized by QIAGEN and moderated by Dr. Pankaj Seth, covering a technical talk by a QIAGEN scientist followed by a scientific talk by Dr. Dipak Sarkar on implementation of QIAGEN technologies. The SNIP conference commenced with the inauguration and warm welcome from Dr. Steve Goodman, Vice-Chancellor, Research, UTHSC, followed by the DISC session with a special talk from by Dr. Okeoma Chioma on SIV and Δ9-THC induced alterations in host miRNAome. DISC session organized by DISC chair Dr. Sowmya V. Yelamanchili also had eight short presentations by DISC-ECI.

On June 2nd, the meeting was formally inaugurated by Dr. Kennard Brown, Executive Vice Chancellor and Chief Operations Officer, UTHSC, followed by Dr. Sulie L. Chang, SNIP President and Professor of Biological Sciences and Director of Institute of NeuroImmune Pharmacology, Seton Hall University. There were four symposia, starting with the President Symposium on “SARS-CoV-2: Comorbidities and therapeutics,” including a plenary lecture by Dr. Colleen Jonsson on “SARS-CoV-2: Past, present, and future,” followed by four talks on SARS-CoV-2 effect on cerebrovascular pathology, neurological dysfunction, and neuropsychiatric complications, and COVID-19 in immunocompromised pediatric populations. The symposium was co-chaired by Dr. Kendall Bryant, and Dr. Jeymohan Joseph. The second symposium on “Use of iPSC-derived CNS cells and brain organoids to model HIV infection, substance use, and ARV treatment in the CNS,” was organized and co-chaired by Dr. Kelly Jordan-Sciutto and Dr. Wenzhe Ho. The symposium focused on how the iPSC-derived CNS cells and brain organoids is used in modeling neuroHIV in the context of antiretroviral therapy (ART) as well as substance abuse. The third symposium, “T time for neuroimmune pharmacology research,” was organized and co-chaired by Dr. Marta Catalfamo, and Dr. Sanjay B. Maggirwar, which included presentations from graduate students and post-doctorate fellows who are the trainees on T-series NIH grants. The fourth symposium “Meet the *NeuroImmune Pharmacology and Therapeutics* (*NIPT*) Editors,” was organized and chaired by Dr. Howard E. Gendelman, Editor-in-Chief of our newly launched SNIP journal, NeuroImmune Pharmacology and Therapeutics (NIPT) and Dr. Jean M. Bidlack. There were five talks in this symposium from the editors of the journal covering several topics from HIV cure strategies, HIV brain reservoirs, COVID-19 post-acute sequelae, gut-brain axis in substance abuse and strategies to halt neurodegenerative diseases. At the end of the session, Dr. Gendelman discussed the vision of

the new journal, NIPT. On the second day of the conference, there were also the special talks presented in the memory of Dr. Bill Narayan, a legend in the field of neurovirology, and Dr. Adarsh Kumar, who had been an ambassador of supporting SNIP young investigators. The Bill Narayan Memorial Lecture was delivered by Dr. Yuri Persidsky, a former president of SNIP, on the role of alcohol and e-cigarettes in blood-brain barrier (BBB) injury. The Adarsh Kumar Lecture was delivered by former Secretary of SNIP, Dr. Shilpa Buch, on the role of exosomes on neuroHIV and opioids comorbidity.

On June 3rd, there were again four symposia, starting with a local symposium organized by UTHSC and Meharry Medical College (MMC) leadership team and chaired by Drs. Chandravanu Dash and Anna Bukia. Plenary talk by Dr. Alex Dopico was on “Ionic mechanisms of alcohol-induced brain hypoperfusion” was followed by four other talks on drugs of abuse and brain function. The second symposium was for ECI that consisted of talks from five pre-doctoral and five postdoctoral fellows, and this symposium was chaired by Drs. Gurudatt Pendyala and Yisel Cantres-Rosario. The ECI symposium was followed by an ECI speed mentoring session to prepare the young investigators for a successful academic career. There was a business meeting that was run by SNIP Secretary, Dr. Jean Bidlack, where all interested SNIP members participated, and the business meeting ended with the transition from the current councils to the newly elected councils. The third symposium on “HIV and neurological diseases,” was co-chaired by Drs. Syed Ali and Ranga V Srinivas. The symposium consists of four talks on neuroHIV and its comorbidities, such as, stroke and Alzheimer’s disease and drugs of abuse. The last symposium organized and co-chaired by Drs. Jerel Fields and Susmita Sil consisted of nine talks from selected abstracts submitted by SNIP members. The conference ended with President’s transition, thank you note from Drs. Sulie Chang and Santosh kumar, and the award ceremony for the best posters and talks.

ECI speed mentoring session

2022 SNIP Meeting
ECI and DISC travel awards

by Gurudutt Pendyala, Ph.D. and Sowmya V. Yelamanchili, Ph.D.

The Early Career Investigator Travel Award (ECITA) committee has been a significant pillar of SNIP lending incredible support to junior investigators at different tiers of their career. True to its motto *"to forge interdisciplinary research and accelerate the bi-directional exchange between early career basic and clinical scientists",* this committee at every annual SNIP meetings has been providing ideal platform for them to access information, gain insight and perspective from their peers as well as identify helpful resources for advancing their careers. To help meet these goals, ECITA has a long-standing tradition to support these "rising stars" by offering travel awards that waive their registration and/or travel including disseminating their research as part of the young investigator forum.

TALK TITLE	University	Name	Mentor	Education Status
ECITA PRE DOCTORAL STUDENTS				
IN UTERO OPIOID EXPOSURE INDUCED VULNERABILITY TO LATER LIFE BRAIN INJURY.	University of Nebraska Medical Center	Austin Gowen	Sowmya Yelamanchili	Graduate Student
USING IPA TOOLS TO CHARACTERIZE MOLECULAR PATHWAYS UNDERLYING THE INVOLVEMENT OF IRF7 IN ANTIVIRAL RESPONSE TO HIV.	Seton Hall University	Nikhil Kota	Sulie Chang	Undergraduate Student
CHIMERIC R5 SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS SHIV.D REPLICATES IN THE BRAIN, CAUSES NEUROPATHOGENESIS, AND PERSISTS ON ANTIRETROVIRAL THERAPY IN RHESUS MACAQUES.	Temple University	Rachel Podgorski	Tricia Burdo	Graduate Student
SYNTHESIS AND CHARACTERIZATION OF A PLGA BASED CANNABIDIOL (CBD) NANOFORMULATION TO TREAT NEUROPATHIC PAIN.	University at Buffalo	Sana Qayum	Supriya Mahajan	Graduate Student
INVESTIGATING SYNAPTIC PRUNING BY GLIA IN HIV ASSOCIATED NEUROLOGICAL DYSFUNCTION.	University of Texas Medical Branch	Zachary Watson	Shao Jun Tang	Graduate Student
ECITA POST DOCTORAL & ESI				
DISCOVERY AND FUNCTIONAL CHARACTERIZATION OF HIV-1-LATENCY ASSOCIATED CIRCULAR RNAS IN AFRICAN AMERICAN WOMEN LIVING WITH HIV.	Temple University	Anna Bellizzi	Ilker Sariyer	Postdoctoral Fellow
METHAMPHETAMINE INDUCES THE RELEASE OF PROADHESIVE EXTRACELLULAR VESICLES AND PROMOTES SYNCYTIA FORMATION: A POTENTIAL ROLE IN HIV-1 NEUROPATHOGENESIS.	University of Nebraska Medical Center	Subhash Chand	Sowmya Yelamanchili	Instructor
MU OPIOID RECEPTOR-MEDIATED RELEASE OF ENDOLYSOSOME IRON INCREASES LEVELS OF MITOCHONDRIAL IRON, REACTIVE OXYGEN SPECIES, AND CELL DEATH.	University of North Dakota	Peter Halcrow	Jonathan Geiger	Postdoctoral Fellow
ABNORMAL BRAIN DIFFUSIVITY IN PARTICIPANTS WITH PERSISTENT NEUROPSYCHIATRIC SYMPTOMS AFTER COVID-19.	University of Maryland School of Medicine	Huajun Liang	Linda Chang	Postdoctoral Fellow
DISRUPTION OF CHOICE: ECOHIV INNOCULATION FOLLOWING A HISTORY OF COCAINE USE.	University of South Carolina	Kristen McLaurin	Rose Booze	Postdoctoral Fellow
DISC- ECITA (PRE AND POST DOCS)				
MONOCYTE BIOMARKERS DEFINE SARGRAMOSTIM TREATMENT OUTCOMES FOR PARKINSON'S DISEASE.	University of Nebraska Medical Center	Mai Mostafa Abdelmoaty	Howard Gendelman	Graduate Student
BRIEF HYDROMORPHONE EXPOSURE DURING PREGNANCY SUFFICIENT TO INDUCE MATERNAL AND NEONATAL MICROBIAL DYSBIOSIS.	University of Miami	Yaa Abu	Sabita Roy	Graduate Student
AN INTEGRATED SYSTEMS APPROACH TO DECODE THE IMPACT OF ADOLESCENT NICOTINE EXPOSURE IN PRE AND POSTNATAL OXYCODONE EXPOSED OFFSPRING.	University of Nebraska Medical Center	Adrian Flores	Gurudutt Pendyala	Graduate Student
HIV PRE-EXPOSURE PROPHYLAXIS (PREP) INHIBITS OLIGODENDROCYTE DIFFERENTIATION.	University of Pennsylvania	Caela Long	Kelly Jordan-Sciutto	Graduate Student
ROLE OF ASTROCYTE-SPECIFIC NLRP6 INFLAMMASOME IN METHAMPHETAMINE-MEDIATED NEUROINFLAMMATION.	University of Nebraska Medical Center	Abiola Oladapo	Palsamy Periyasamy/Shilpa Buch	Graduate Student
CB2R AGONIST JWH-133 DECREASES CATB SECRETION AND NEUROTOXICITY FROM HIV-INFECTED MACROPHAGES BY ATTENUATING NF-KB ACTIVATION, OXIDATIVE STRESS, AND LYSOSOMAL EXOCYTOSIS.	University of Puerto Rico, Medical Sciences Campus	Lester Rosario-Rodríguez	Loyda Melendez	Postdoctoral Fellow
SERPIN-DERIVED PEPTIDE FOR THE TREATMENT AGAINST HIV IN THE CNS.	Florida International University	Yemmy Soler	Nazira El-Hage	Graduate Student
METHAMPHETAMINE AND THE S1 SUBUNITS OF SARS COV-2 VARIANT SPIKE PROTEINS DYSREGULATE HUMAN BRAIN ENDOTHELIAL CELLS.	University of Miami Miller School of Medicine	Michael Stangis	Michal Toborek	Graduate Student

2022 SNIP Meeting
ECI and DISC travel awards

by Gurudutt Pendyala, Ph.D. and Sowmya V. Yelamanchili, Ph.D.

Best Oral Presentation		
Name	**Mentor**	**Institute**
Austin Gowen	Sowmya Yelamanchili	UNMC
Huajun Liang	Linda Chang	U Maryland
Best Oral Presentation - DISC		
Name	**Mentor**	**Institute**
Yaa Abu	Sabita Roy	U Miami
Mai Mostafa Abdelmoaty	Howard Gendelman	UNMC
Arthur Falek Best Poster Presentation		
Name	**Mentor**	**Institute**
Alexis Brantly	Michael Nonnemacher	Drexel University
David Ajasin	Eliseo Eugenin	UTMB
NIPT-SNIP Research Awards		
Name	**Mentor**	**Institute**
Yaa Abu	Sabita Roy	U Miami
Peter Halcrow	Jonathan Geiger	U North Dakota
Yemmy Soler	Nazira El-Hage	Florida Int. University
Kristen McLaurin	Rosemary Booze	U South Carolina
Nikhil Kota	Sulie Chang	Seton Hall University

ECI-awardees

ECI-DISC awardees

Pluripotent stem cell-based platforms: overcoming old challenges while providing new opportunities

Kimberly Christian[1] and Cagla Akay-Espinoza[2]
[1] Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
[2] Department of Oral Medicine, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA

Advances in generating human induced pluripotent stem cells (iPSCs) from skin fibroblasts of healthy human adult donors provide exciting opportunities to address challenges faced in a myriad of contexts in neuroscience, ranging from neurodevelopment to neurodegeneration[1]. 2D and 3D models based on human iPSCs provide an important new platform for the interrogation of cellular, molecular, and genetic drivers in systems that more closely recapitulate the key determinants of development and disease in the central nervous system (CNS)[2].



Utility of 2D and 3D human iPSC platforms in CNS development and disease
PSC, pluripotent stem cell; NPC, neural progenitor cell; HTC, high-throughput screening
Originally published in: LaNoce E, Dumeng-Rodriguez J, Christian KM. Using 2D and 3D pluripotent stem cell models to study neurotropic viruses. Frontiers in Virology. 2022.

Early control of viral replication and immune recovery achieved with antiretroviral therapy (ART) has vastly improved outcomes in people living with HIV infection (PLWH); however, up to 50% of PLWH continue to experience neurocognitive impairment (NCI) and other neurological disorders and are at higher risk for progression to more severe NCI[3,4]. Viral suppression requires strict adherence to ART and rebound viremia occurs within 4-8 weeks upon treatment interruption in the majority of cases[5-7]. Additionally, while ART has proven highly effective at quelling viral replication, certain antiretroviral drugs (ARVs) can also contribute to a number of substantial health issues including inflammation and neurodevelopmental disorders[8-11]. Eradicative cure, which remains a public health priority, requires elimination of virus reservoirs from all tissues including the central nervous system while ensuring the development of ARVs with fewer toxicities. These efforts should utilize models that closely recapitulate the key characteristics of specialized cell populations and their interactions in the CNS. Until recently, studies on HIV infection and ART in the CNS have been mainly limited to laboratory animal and postmortem studies. Models based on human iPSCs provide new opportunities for *in vitro* mechanistic studies of interactions among neurons, microglia, and astrocytes during HIV infection in an appropriate CNS context. In Symposium 1 chaired by Kelly Jordan-Sciutto and Wenzhe Ho, four speakers presented data illustrating the utility of human iPSC-based models in examining HIV infection, the impact of ARVs on CNS outcomes, and the genetic determinants of alcohol use disorder in neurons.

Kimberly Christian[1] and Cagla Akay-Espinoza[2]
[1] Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
[2] Department of Oral Medicine, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA

Cagla Akay-Espinoza presented evidence that models based on hiPSC-derived neurons, astrocytes, and microglia can be utilized to examine the replication dynamics of HIV in microglia, to understand the direct and indirect effects of HIV on specific cell types, and to assess the impact of ART on cellular outcomes in a system that more closely recapitulates the key determinants of HIV infection in the CNS[12]. Kimberly Christian described an ongoing study to investigate the impact of dolutegravir on early neurodevelopment using a forebrain organoid model of fetal brain development, which illustrates the utility of these human iPSC models to evaluate the safety and potential off-target effects of therapeutic drugs[13]. In his talk, Ronald Hart highlighted the ability to interrogate the contribution of certain risk variants of *KCNJ6* to neuronal function by leveraging iPSC-derived neurons, with the future goal of developing optimal therapies based on specific genetic variants[14]. Brittany Bodnar presented a model of cortical organoids with integrated microglia that were susceptible to HIV infection, demonstrating a viable platform to study neuro-immune interactions with the most relevant human CNS cell types[15]. Together, these talks highlighted several potential applications of human iPSC models to better understand disease etiology, virus-host interactions, and genetic susceptibility to neurological disorders and pathology, as well as screening for drug safety and efficacy. Although many challenges remain in the field to model all of the physiological factors that may contribute to variability in response to viral infections and drug treatment, the current technology is exciting and provides unprecedented opportunities to move towards personalized medicine with better diagnostic and therapeutic outcomes.

References

1. Marei HE, Althani A, Lashen S, Cenciarelli C, Hasan A. Genetically unmatched human iPSC and ESC exhibit equivalent gene expression and neuronal differentiation potential. Scientific reports. 2017;7(1):17504.
2. LaNoce E, Dumeng-Rodriguez J, Christian KM. Using 2D and 3D pluripotent stem cell models to study neurotropic viruses. Frontiers in Virology. 2022.
3. Grant I, Franklin DR, Jr., Deutsch R, Woods SP, Vaida F, Ellis RJ, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014;82(23):2055-62.
4. Gao C, Meng J, Xiao X, Wang M, Williams AB, Wang H. Antiretroviral therapy improves neurocognitive impairment in people living with HIV? A meta-analysis. Int J Nurs Sci. 2020;7(2):238-47.
5. Cory TJ, Schacker TW, Stevenson M, Fletcher CV. Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS. 2013;8(3):190-5.
6. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Medicine. 2003;9(6):727-8.
7. Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS (London, England). 2016;30(3):343-53.
8. Underwood J, Robertson KR, Winston A. Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease? AIDS (London, England). 2015;29(3):253-61
9. Vannappagari V, Koram N, Albano J, Tilson H, Gee C. Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry. BJOG: An International Journal of Obstetrics & Gynaecology. 2016;123(6):910-6.
10. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. New England Journal of Medicine. 2016;375(18):1726-37
11. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. The New England journal of medicine. 2018;379(10):979.
12. Ryan SK, Gonzalez MV, Garifallou JP, Bennett FC, Williams KS, Sotuyo NP, et al. Neuroinflammation and EIF2 Signaling Persist despite Antiretroviral Treatment in an hiPSC Tri-culture Model of HIV Infection. Stem Cell Reports. 2020.
13. Schnoll JG, Temsamrit B, Zhang D, Song H, Ming G-l, Christian KM. Evaluating neurodevelopmental consequences of perinatal exposure to antiretroviral drugs: current challenges and new approaches. Journal of Neuroimmune Pharmacology. 2021;16(1):113-29.
14. Popova D, Gameiro-Ros I, Youssef MM, Zalamea P, Morris AD, Prytkova I, et al. Alcohol reverses the effects of KCNJ6 (GIRK2) noncoding variants on excitability of human glutamatergic neurons. bioRxiv. 2022.
15. Bodnar B, Zhang Y, Liu J, Lin Y, Wang P, Wei Z, et al. Novel scalable and simplified system to generate microglia-containing cerebral organoids from human induced pluripotent stem cells. Frontiers in cellular neuroscience. 2021:206.

SNIP'S OFFICIAL JOURNAL
"NEUROIMMUNE PHARMACOLOGY & THERAPEUTICS"

Dear Editors, Authors, and Readers of our NeuroImmune Pharmacology and Therapeutics Journal,

Greetings! We are excited to launch our Journal bringing it to our *Society on NeuroImmune Pharmacology (SNIP)*, our world-wide colleagues, students, faculties, and the scientific community at large. Our "in person" 26th Scientific Conference was a raging success with shared friendship and science a short time past in Memphis, Tennessee.

I would like to take this opportunity to update our readership on the birth of our new official journal. This letter serves to welcome the new Society-owned open-access journal, *NeuroImmune Pharmacology and Therapeutics (NIPT)*.



Please let us take you through the history that led us to this occasion and our cause for celebration. Since the start of 2022, our SNIP Journal Publication Committee (JPC, Drs. Santosh Kumar, Sanjay Maggirwar and Jean M. Bidlack) worked diligently and thoughtfully with *NIPT*'s founding Editor-in-Chief and the publishers, De Gruyter and the University of Nebraska Press. We read, reviewed, and edited many versions of agreements and operational plans. To this end, we must thank each for their wisdom, patience, and thoughtfulness throughout. This culminated in a Journal Publishing Agreement signed on April 27, 2022. We are pleased to announce that *NIPT* has been accepting manuscripts for peer-reviewed publication. Our editors have pledged to keep reviews to a maximum of two weeks with rapid online publication. To celebrate the birth of *NIPT*, we are pleased to announce that the total costs of open access will be paid by the journal in total for the first two years of operation.

Working with many of you through these tumultuous COVID-19 pandemic years has been a challenging and rewarding journey capped with *NIPT's* launch and SNIP's recent conference. After 17 years of SNIP's direct support in review, board membership, and sustained manuscript submissions at *the Journal of Neuroimmune Pharmacology* (*JNIP)*, many have asked why launch a new journal? *JNIP* was certainly aligned with our Society but owned elsewhere. A new opportunity allowed us to develop new policies and broaden the publishing process. Factors underlying the change of SNIP's official journal included:

1. Broaden our abilities to accept a wide range of manuscripts.
2. Improve production times for the online publication and notably for high-impact accepted manuscripts which will garner broad interest and broaden our field.
3. Make funds available that will compensate our editors for their due diligence, time, and effort into supporting the Journal's activities.
4. Facilitate direct engagement by society leadership in broad decision-making, support, direction, and input when needed in steering and appointing the Journal's leadership including the Editor-in-Chief.
5. Facilitate the growth of our field, our authors, reviewers and editors for open contracts and future growth, discussion, and needed negotiations.
6. To begin the open-access journal, substantial moneys already raised from private donors to cover the Article Processing Charges (APCs) for all submissions the first years of operation.
7. Make available immediately open-access submissions free of charge to both members and non-member scientists worldwide. These philanthropic supporters have also contributed to early-career investigator awards at the 2022 SNIP conference and announced in Memphis.
8. Although PubMed indexing will be delayed by up to 18 months during the infancy stage of *NIPT*, the indexing will be applied retroactively to all accepted/published manuscripts. In addition, when NIH funding is acknowledged, our *NIPT* articles will be registered in PubMed Central (PMC) and therefore available in all PubMed searches. NIH-funded manuscripts will not face any delays. All NIH-funded manuscripts will be indexed promptly in PubMed Central to comply with the NIH Public Access Policy.

SNIP'S OFFICIAL JOURNAL
"NEUROIMMUNE PHARMACOLOGY & THERAPEUTICS"

Please read the NIPT's online presence by visiting the SNIP's publication page (https://s-nip.org/publications), our ScholarOne submission portal (https://mc.manuscriptcentral.com/nipt), and the *NIPT* website via De Gruyter (https://www.degruyter.com/journal/key/nipt/html).

Our editor-in-chief, senior editors, and section editors from *JNIP* are now at *NIPT*, along with several new editor additions. Our Society benefits from their experienced leadership. The roster of senior and section editors can be found under the "Editorial" tab of our *NIPT* website published online by De Gruyter. In addition, the SNIP JPC members are serving on an advisory board for *NIPT*. They are joined by philanthropic supporters who have made the launch of SNIP's very own open-access journal possible. Attached, you can find the editors and advisory board governing the journal.

The name of *NIPT* has retained the capitalization style of our Society, with the "I" capitalized in "NeuroImmune." The *NIPT* name also reflects the evolving new frontier of therapeutics in the field of neuroimmune pharmacology. Furthermore, open access is the future of scholarly publishing, and this SNIP-owned journal ensures that the Society will have ownership in the development of our journal for the benefit of future generations of scientists. The journal's open-access publishing model will facilitate universal access to accepted/published manuscripts by anyone anywhere in the world. This will give authors and contributors from our Society a much larger global audience at an affordable rate from one of the world's oldest scholarly publishers, De Gruyter. Subsequent print publication of the online-first journal is in development with the University of Nebraska Press. Several theme issues for *NIPT* are already in development with invited Guest Editors. As would be expected, all manuscripts will undergo rigorous peer review to uphold our highest scientific standards. All accepted manuscripts will appear immediately on the new journal website hosted by De Gruyter. After waiving APCs for all submissions accepted during the first two years of the journal's operation, we are committed to keeping the price of APCs affordable for our members.

We close this letter with a request to you, our colleagues and reviewers engaged in the field of neuroimmune pharmacology — please always consider *NIPT* as a priority for your publications. We look forward to reviewing and publishing your work. Your excellent contributions will help *NIPT* to a strong start. Together, we will ensure mutual success with this important new endeavor.

Sincerely,

Sulie L. Chang, Ph.D.
President, Society on NeuroImmune Pharmacology (2019-2022)

Howard E. Gendelman, M.D.
Editor-in-Chief, NeuroImmune Pharmacology and Therapeutics Journal

Santosh Kumar, Ph.D.
President, Society on NeuroImmune Pharmacology (2022-2023)

UPCOMING 2023 SNIP MEETING IN NEW DELHI

Announcements

Postdoc/Research Associate/Ph.D. student
Neuron-Glia Interaction in Pathogenesis of HIV-Associated Pain
Stony Brook University

A position is available immediately in the Stony Brook University Pain and Analgesia Research Center (SPARC) and the Department of Anesthesiology of Stony Brook University at Long Island, New York. The candidate will participate in an exciting project to determine the role of neuron-glia interaction in pain pathogenesis associated with HIV infection and comorbidities (e.g., antiretroviral therapy and opioid use), and will have opportunities to use integrated interdisciplinary approaches of single cell analysis, mouse genetics, molecular biology, electrophysiology, behavioral testing, and imaging in mechanistic and/or translational research. The Stony Brook University campus offers a rich and collaborative environment for HIV, neuroscience, and pain research and is close to numerous beaches and nature reserves. The suitable candidate is expected to have a strong background in at least one of the following areas: HIV and molecular biology, neurobiology and/or developmental biology, bioinformatics and/or computer science, or immunostaining/RNA in situ and confocal imaging. Interested candidates should email a single PDF file containing a CV, a personal statement describing research interests and goals, and contact information for three references to: Shao-Jun Tang, Email: shao.tang@stonybrookmedicine.edu

Postdoc/Research Scientist position
Temple University Lewis Katz School of Medicine.

Department of Microbiology, Immunology, and Inflammation will be providing comprehensive coordination of research projects and analysis related to molecular neuroscience and addictive stimulants on the brain of patients infected with the human immunodeficiency virus HIV-1. The Postdoc or Research Scientist will be performing biological/molecular research using techniques such as cell transfection, RT-PCR, viability assays, cell culture maintenance, immunohistochemistry, gene editing, protein analysis using biochemical techniques and bioinformatics including both RNA sequencing and electrophysiological data processing. The candidate will also be providing complex technical assistance involving microelectrode array analysis of neuronal cell function and action potential of other cell types to principal investigators in support of research activities; and managing the day-to-day research studies and general data collection.
Required Education and Experience: Ph.D. in Biology, Bioengineering/Chemical Engineering, Genetics, Biochemistry, or Molecular Biology and at least four years of experience in the field of biomedical research/molecular neuroscience. An equivalent combination of education and experience may be considered.
Interested applicant should send (1) resume, (2) a one-page summary of previous research experience, and (3) : three letters of recommendation directly to Dr. Ilker K. Sariyer (isariyer@temple.edu) and Dr. Kamel Khalili (kamel.Khalili@temple.edu).